Experimental pathway gene signatures and overlap with the MPH dataset.

<p>^a Pathway gene signatures were defined as all genes up or downregulated ≥ 2-fold across all 12 and 24 h time points, relative to untreated controls.</p><p>^b IDs for PDGF, TGFβ, S1P, IL-13, IL-4, and RZN denote unique Agilent probe IDs. Entrez gene IDs were used for LPS, PolyIC, TNFα, IFNα, Iono-PMA, Dex, and imatinib; all genes represented by two or more probes were averaged in both the MPH dataset and individual gene signatures.</p><p>^c The gene expression signature used for imatinib was determined based upon a p value cutoff, as defined by Chung, <i>et al</i>. [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114017#pone.0114017.ref005" target="_blank">5</a>].</p><p>^d MPH overlap signifies the number of genes IDs from a given pathway also appearing in the MPH dataset; the low overlap percentages seen in both PDGF and PPARγ pathways is a result of platform differences, as both PDGF and PPARγ pathways were reanalyzed on Agilent 8 × 60k DNA microarrays, while the MPH dataset includes only probes present in both 44k and 60k arrays.</p><p>Experimental pathway gene signatures and overlap with the MPH dataset.